Enanta Pharmaceuticals Inc., a clinical-stage biotechnology company, reported financial results for its fiscal second quarter ending March 31, 2025. The company recorded a net loss of $22.6 million, or a loss of $1.06 per diluted common share, compared to a net loss of $31.2 million, or a loss of $1.47 per diluted common share, for the same period in 2024. Enanta's cash, cash equivalents, and short-term marketable securities stood at $193.4 million as of March 31, 2025. The company anticipates that its current cash reserves, combined with a $33.8 million federal income tax refund received in April 2025, will be sufficient to fund its existing operations and development programs into fiscal 2028. In terms of business updates, Enanta highlighted progress in its virology pipeline, with the completion of target enrollment for its RSVHR Phase 2 study of zelicapavir in high-risk adults infected with Respiratory Syncytial Virus (RSV). The company is on track to report topline data from this study in the late third quarter of 2025. Enanta continues to focus on developing oral antiviral treatments for serious infections, with its RSV assets, including zelicapavir and EDP-323, both in Phase 2 development. The company is evaluating potential partnership opportunities to further develop these assets. Additionally, the STAT6 program is progressing with plans to select a development candidate in the second half of 2025, while IND enabling studies of the KIT inhibitor EPS-1421 are ongoing.